MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 01-13-2026
Bio-Path Holdings Operating Income 2011-2026 | BPTH
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Bio-Path Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.8 M | -13.9 M | -10.4 M | -10.9 M | -8.69 M | -8.59 M | -8.97 M | -8.48 M | -5.48 M | -4.54 M | -3.27 M | -2.58 M | -2.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.37 M | -15.8 M | -8 M |
Quarterly Operating Income Bio-Path Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -488 K | -4.56 M | -3.24 M | - | -2.63 M | -3.04 M | -3.7 M | - | -3.28 M | -4.24 M | -5.29 M | - | -3.55 M | -3.01 M | -3.36 M | - | -2.07 M | -1.81 M | -2.45 M | - | -2.97 M | -2.04 M | -3.34 M | - | -2.27 M | -2.49 M | -1.52 M | - | -3.08 M | -1.68 M | -1.92 M | - | -2.48 M | -2.32 M | -2 M | -1.67 M | -2.99 M | -1.94 M | -1.87 M | -1.46 M | -1.51 M | -1.13 M | -1.38 M | -1.6 M | -1.15 M | -1.27 M | -510 K | -791 K | -1.39 M | -429 K | -656 K | - | -840 K | -788 K | -523 K | - | -504 K | -464 K | -593 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -429 K | -5.29 M | -2.05 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 14.93 | 0.88 % | $ 219 M |  USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.14 | 0.36 % | $ 443 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-76.3 M | $ 8.39 | 4.5 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
-41 M | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
argenx SE
ARGX
|
-349 M | $ 749.68 | 0.44 % | $ 25 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 23.93 | 1.27 % | $ 3.04 B | USA |
 |
Arvinas
ARVN
|
-118 M | $ 11.36 | 4.7 % | $ 805 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
98.3 M | $ 61.99 | 1.57 % | $ 8.29 B | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Assembly Biosciences
ASMB
|
-12.1 M | $ 29.09 | 0.28 % | $ 326 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Actinium Pharmaceuticals
ATNM
|
-36.2 M | $ 1.13 | 15.26 % | $ 35.3 M | USA |
 |
Atossa Therapeutics
ATOS
|
-37.1 M | $ 5.19 | -3.36 % | $ 44.7 M | USA |
 |
Atara Biotherapeutics
ATRA
|
35.9 M | $ 5.0 | 0.2 % | $ 62.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aurinia Pharmaceuticals
AUPH
|
33.2 M | $ 16.05 | 2.79 % | $ 2.16 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.41 | -0.35 % | $ 375 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 411.97 | -0.2 % | $ 31.2 B | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
BioCardia
BCDA
|
-8.28 M | $ 1.18 | -1.67 % | $ 7.87 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-2.54 M | $ 9.59 | 6.26 % | $ 1.98 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-51.4 M | $ 3.05 | 1.51 % | $ 260 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 9.46 | -3.47 % | $ 612 M | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.46 | 2.81 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-24.8 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
409 M | $ 56.04 | 0.96 % | $ 10.7 B | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 91.64 | 0.5 % | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-50.5 M | $ 1.18 | -0.42 % | $ 14.4 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 4.5 | 8.57 % | $ 683 M | Britain |